Back to mobile site

Citi Reiterates Buy Rating on Prime Medicine (PRME)

September 30, 2024 4:02 PM EDT Send to a Friend
Citi analyst Samantha Semenkow reiterated a Buy rating and $10.00 price target on Prime Medicine (NASDAQ: PRME).The analyst comments "This ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login